NASDAQ:CYTK Cytokinetics (CYTK) Stock Price, News & Analysis $80.74 -1.18 (-1.44%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$80.73 -0.01 (-0.01%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cytokinetics Stock (NASDAQ:CYTK) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cytokinetics alerts:Sign Up Key Stats Today's Range$80.28▼$82.5950-Day Range$67.07▼$87.2652-Week Range$32.89▼$88.31Volume1.64 million shsAverage Volume2.06 million shsMarket Capitalization$10.05 billionP/E RatioN/ADividend YieldN/APrice Target$99.90Consensus RatingModerate Buy Company Overview Cytokinetics, Inc. is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need. The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility. In parallel, Cytokinetics has advanced reldesemtiv, a skeletal muscle activator, into clinical development for neuromuscular disorders such as amyotrophic lateral sclerosis and spinal muscular atrophy. A third key program, apitegromab, seeks to preserve and restore muscle function in patients with muscle‐wasting diseases by inhibiting myostatin activation. Beyond these lead assets, Cytokinetics maintains a pipeline of early‐stage candidates targeting both cardiac and skeletal muscle biology. While based in the United States, Cytokinetics conducts clinical trials across North America, Europe and Asia, and has forged strategic collaborations with major biopharmaceutical firms to support global development and commercialization. Led by a management team with extensive experience in drug discovery, clinical development and regulatory affairs, the company continues to expand its scientific platform and pursue strategic partnerships. Through its targeted approach to muscle biology, Cytokinetics seeks to bring new therapeutic options to patients suffering from debilitating cardiac and neuromuscular diseases.AI Generated. May Contain Errors. Read More Cytokinetics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreCYTK MarketRank™: Cytokinetics scored higher than 70% of companies evaluated by MarketBeat, and ranked 221st out of 836 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCytokinetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 2 strong buy ratings, 17 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialCytokinetics has a consensus price target of $99.90, representing about 23.7% upside from its current price of $80.74.Amount of Analyst CoverageCytokinetics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cytokinetics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cytokinetics are expected to grow in the coming year, from ($6.20) to ($4.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytokinetics is -11.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytokinetics is -11.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Cytokinetics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.07% of the float of Cytokinetics has been sold short.Short Interest Ratio / Days to CoverCytokinetics has a short interest ratio ("days to cover") of 8.99.Change versus previous monthShort interest in Cytokinetics has recently decreased by 2.97%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCytokinetics does not currently pay a dividend.Dividend GrowthCytokinetics does not have a long track record of dividend growth. News and Social Media3.9 / 5News Sentiment1.17 News SentimentCytokinetics has a news sentiment score of 1.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Cytokinetics this week, compared to 12 articles on an average week.Search Interest5 people have searched for CYTK on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat Follows3 people have added Cytokinetics to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Cytokinetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,816,694.00 in company stock.Percentage Held by Insiders2.60% of the stock of Cytokinetics is held by insiders.Percentage Held by InstitutionsCytokinetics has minimal institutional ownership at this time.Read more about Cytokinetics' insider trading history. Receive CYTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CYTK Stock News HeadlinesCytokinetics to Announce Second Quarter Results on August 6, 2026July 24 at 7:12 AM | markets.businessinsider.comCytokinetics: Label Expansion Can Turn MYQORZO Into An HCM FranchiseJuly 22 at 2:00 PM | seekingalpha.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.July 25 at 1:00 AM | Porter & Company (Ad)Cytokinetics CEO on the launch of its first commercial drugJuly 21, 2026 | finance.yahoo.comCytokinetics (NASDAQ:CYTK) CEO Sells 7,500 Shares of StockJuly 15, 2026 | insidertrades.comFady Ibraham Malik Sells 3,500 Shares of Cytokinetics (NASDAQ:CYTK) StockJuly 8, 2026 | insidertrades.comCytokinetics (NASDAQ:CYTK) EVP Sells 1,112 SharesJuly 3, 2026 | insidertrades.comCytokinetics (NASDAQ:CYTK) EVP Sung Lee Sells 3,134 SharesJune 30, 2026 | insidertrades.comSee More Headlines CYTK Stock Analysis - Frequently Asked Questions How have CYTK shares performed this year? Cytokinetics' stock was trading at $63.54 at the beginning of 2026. Since then, CYTK shares have increased by 27.1% and is now trading at $80.74. How were Cytokinetics' earnings last quarter? Cytokinetics, Incorporated (NASDAQ:CYTK) posted its earnings results on Tuesday, May, 5th. The biopharmaceutical company reported ($1.67) earnings per share for the quarter, hitting analysts' consensus estimates of ($1.67). The firm's revenue was up 1112.5% on a year-over-year basis. Read the conference call transcript. Who are Cytokinetics' major shareholders? Top institutional investors of Cytokinetics include Handelsbanken Fonder AB (0.33%), E. Ohman J or Asset Management AB (0.24%), Mirador Capital Partners LP (0.16%) and Tema ETFs LLC (0.02%). Insiders that own company stock include Robert I Blum, Fady Ibraham Malik, John T Henderson, Sung Lee, Andrew Callos, Wendell Wierenga, Wendall Wierenga, Muna Bhanji, Robert Arthur Harrington, Robert Wong, B Lynne Parshall and Edward M Md Kaye. View institutional ownership trends. How do I buy shares of Cytokinetics? Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cytokinetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cytokinetics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD), Advanced Micro Devices (AMD), Adobe (ADBE) and GE Aerospace (GE). Company Calendar Last Earnings5/05/2026Today7/25/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (10m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 CYTK's financial health is in the Green zone, according to TradeSmith. CYTK has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CYTK CIK1061983 Webwww.cytokinetics.com Phone(650) 624-3000Fax650-624-3010Employees250Year Founded1998Price Target and Rating Average Price Target for Cytokinetics$99.90 High Price Target$140.00 Low Price Target$56.00 Potential Upside/Downside+23.7%Consensus RatingModerate Buy Rating Score (0-4)2.91 Research Coverage22 Analysts Profitability EPS (Trailing Twelve Months)($6.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$784.96 million Net Margins-784.02% Pretax Margin-784.02% Return on EquityN/A Return on Assets-52.86% Debt Debt-to-Equity RatioN/A Current Ratio4.21 Quick Ratio4.21 Sales & Book Value Annual Sales$88.04 million Price / Sales114.11 Cash FlowN/A Price / Cash FlowN/A Book Value($5.39) per share Price / Book-14.98Miscellaneous Outstanding Shares124,430,000Free Float121,198,000Market Cap$10.05 billion OptionableOptionable Beta0.42 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:CYTK) was last updated on 7/25/2026 by MarketBeat.com Staff. From Our PartnersReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | SponsoredBuy this stock tomorrowMarc Chaikin, founder of Chaikin Analytics, is flagging a little-known company that just secured a partnership...Chaikin Analytics | SponsoredBlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...Awesomely | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytokinetics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
